MedTrace Logo

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia

NCT04361032 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2020-08-27

No results posted yet for this study

Summary

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, associated with standards treatments in COVID-19 (+) patients, Hospitalized In Intensive care in Tunisia.

Multicentric, comparative, randomized study.

Conditions

  • COVID19
  • Intensive Care Unit

Interventions

DRUG

Tocilizumab Injection

Tocilizumab (LOC) (8mg/ kg per day) (1 injection per infusion). Only on the 1st day (D0)

DRUG

Deferoxamine

Deferoxamine (Desferal 500 mg, powder, and solvent for IV solution for injection)

Sponsors & Collaborators

  • Eshmoun Clinical Research Center

    collaborator NETWORK

  • Datametrix

    collaborator INDUSTRY

  • Abderrahmane Mami Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-04
Primary Completion
2020-09-04
Completion
2020-10-04

Countries

  • Tunisia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04361032 on ClinicalTrials.gov